Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
История и перспективы развития метода коронарного стентирования (краткий очерк)
История и перспективы развития метода коронарного стентирования (краткий очерк)
Аналеев А.И., Семитко С.П. История и перспективы развития метода коронарного стентирования (краткий очерк). Consilium Medicum. 2016; 18 (10): 34–39. DOI: 10.26442/2075-1753_2016.10.34-39
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Данная статья посвящена истории развития коронарного стентирования, обзору современных технологий и перспективам дальнейшего развития данной методики.
Ключевые слова: коронарный стент, стентирование коронарных артерий, история интервенционной кардиологии, стент с лекарственным покрытием, биорезорбируемые скаффолды.
Ключевые слова: коронарный стент, стентирование коронарных артерий, история интервенционной кардиологии, стент с лекарственным покрытием, биорезорбируемые скаффолды.
________________________________________________
This article is devoted to the history of the development of coronary stenting, review of modern technologies and perspectives for the further development of this technique.
Key words: coronary stent, coronary artery stenting, history of interventional cardiology, drug-eluting stent, bioresorbable scaffolds.
Key words: coronary stent, coronary artery stenting, history of interventional cardiology, drug-eluting stent, bioresorbable scaffolds.
Полный текст
Список литературы
1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1: 263.
2. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1–42.
3. Bauters C, Meurice T, Hamon M et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835–46.
4. Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555–62.
5. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208–15.
6. Yoshida Y, Mitsumata M, Ling G et al. Migration of medial smooth muscle cells to the intima after balloon injury. Ann NY Acad Sci 1997; 811: 459–70.
7. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218–24.
8. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701–6.
9. De Feyter PJ, De Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643–51.
10. Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a selfexpanding coronary-artery stent. N Engl J Med 1991; 324: 13–7.
11. Serruys PW, De Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT study group. N Engl J Med 1994; 331: 489–95.
12. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994; 331: 496–501.
13. Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94: 1247–54.
14. Chen MS, John JM, Chew DP et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260–4.
15. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80.
16. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23.
17. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–31.
18. Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277–83.
19. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636–45.
20. Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag 2007; 3: 191–201.
21. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–21.
22. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27: 2784–814.
23. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440–55. Discussion 1455.
24. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, December 7–8, 2006. Circulation 2007; 115: 2352–7.
25. Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–9.
26. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–33.
27. Morton AC, Crossman D, Gunn J. The influence of physical stent parameters upon restenosis. Pathol Biol (Paris) 2004; 52: 196–205.
28. Amin AP, Spertus JA, Cohen DJ et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med 2012; 172: 1145–52.
29. Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR-II trial. Circulation 2006; 114: 798–806.
30. Serruys PW, Silber S, Garg S et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136–46.
31. Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903–13.
32. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393–402.
33. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163–73.
34. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001; 59: 227–48.
35. Park KW, Kang SH, Velders MA et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J 2013; 165: 241–50 e244.
36. Greenhalgh J, Hockenhull J, Rao N et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 12: CD004587.
37. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P et al. Long-term benefit-risk balance of drug-eluting vs. Bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30: 16–24.
2. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1–42.
3. Bauters C, Meurice T, Hamon M et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835–46.
4. Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555–62.
5. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208–15.
6. Yoshida Y, Mitsumata M, Ling G et al. Migration of medial smooth muscle cells to the intima after balloon injury. Ann NY Acad Sci 1997; 811: 459–70.
7. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218–24.
8. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701–6.
9. De Feyter PJ, De Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643–51.
10. Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a selfexpanding coronary-artery stent. N Engl J Med 1991; 324: 13–7.
11. Serruys PW, De Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT study group. N Engl J Med 1994; 331: 489–95.
12. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994; 331: 496–501.
13. Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94: 1247–54.
14. Chen MS, John JM, Chew DP et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260–4.
15. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80.
16. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23.
17. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–31.
18. Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277–83.
19. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636–45.
20. Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag 2007; 3: 191–201.
21. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–21.
22. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27: 2784–814.
23. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440–55. Discussion 1455.
24. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, December 7–8, 2006. Circulation 2007; 115: 2352–7.
25. Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–9.
26. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–33.
27. Morton AC, Crossman D, Gunn J. The influence of physical stent parameters upon restenosis. Pathol Biol (Paris) 2004; 52: 196–205.
28. Amin AP, Spertus JA, Cohen DJ et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med 2012; 172: 1145–52.
29. Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR-II trial. Circulation 2006; 114: 798–806.
30. Serruys PW, Silber S, Garg S et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136–46.
31. Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903–13.
32. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393–402.
33. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163–73.
34. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001; 59: 227–48.
35. Park KW, Kang SH, Velders MA et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J 2013; 165: 241–50 e244.
36. Greenhalgh J, Hockenhull J, Rao N et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 12: CD004587.
37. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P et al. Long-term benefit-risk balance of drug-eluting vs. Bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30: 16–24.
2. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1–42.
3. Bauters C, Meurice T, Hamon M et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835–46.
4. Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555–62.
5. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208–15.
6. Yoshida Y, Mitsumata M, Ling G et al. Migration of medial smooth muscle cells to the intima after balloon injury. Ann NY Acad Sci 1997; 811: 459–70.
7. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218–24.
8. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701–6.
9. De Feyter PJ, De Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643–51.
10. Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a selfexpanding coronary-artery stent. N Engl J Med 1991; 324: 13–7.
11. Serruys PW, De Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT study group. N Engl J Med 1994; 331: 489–95.
12. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994; 331: 496–501.
13. Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94: 1247–54.
14. Chen MS, John JM, Chew DP et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260–4.
15. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80.
16. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23.
17. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–31.
18. Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277–83.
19. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636–45.
20. Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag 2007; 3: 191–201.
21. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–21.
22. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27: 2784–814.
23. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440–55. Discussion 1455.
24. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, December 7–8, 2006. Circulation 2007; 115: 2352–7.
25. Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–9.
26. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–33.
27. Morton AC, Crossman D, Gunn J. The influence of physical stent parameters upon restenosis. Pathol Biol (Paris) 2004; 52: 196–205.
28. Amin AP, Spertus JA, Cohen DJ et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med 2012; 172: 1145–52.
29. Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR-II trial. Circulation 2006; 114: 798–806.
30. Serruys PW, Silber S, Garg S et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136–46.
31. Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903–13.
32. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393–402.
33. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163–73.
34. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001; 59: 227–48.
35. Park KW, Kang SH, Velders MA et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J 2013; 165: 241–50 e244.
36. Greenhalgh J, Hockenhull J, Rao N et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 12: CD004587.
37. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P et al. Long-term benefit-risk balance of drug-eluting vs. Bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30: 16–24.
________________________________________________
2. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1–42.
3. Bauters C, Meurice T, Hamon M et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835–46.
4. Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555–62.
5. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208–15.
6. Yoshida Y, Mitsumata M, Ling G et al. Migration of medial smooth muscle cells to the intima after balloon injury. Ann NY Acad Sci 1997; 811: 459–70.
7. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218–24.
8. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701–6.
9. De Feyter PJ, De Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643–51.
10. Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a selfexpanding coronary-artery stent. N Engl J Med 1991; 324: 13–7.
11. Serruys PW, De Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT study group. N Engl J Med 1994; 331: 489–95.
12. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994; 331: 496–501.
13. Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94: 1247–54.
14. Chen MS, John JM, Chew DP et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260–4.
15. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80.
16. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23.
17. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–31.
18. Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277–83.
19. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636–45.
20. Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag 2007; 3: 191–201.
21. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–21.
22. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27: 2784–814.
23. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440–55. Discussion 1455.
24. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, December 7–8, 2006. Circulation 2007; 115: 2352–7.
25. Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–9.
26. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–33.
27. Morton AC, Crossman D, Gunn J. The influence of physical stent parameters upon restenosis. Pathol Biol (Paris) 2004; 52: 196–205.
28. Amin AP, Spertus JA, Cohen DJ et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med 2012; 172: 1145–52.
29. Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR-II trial. Circulation 2006; 114: 798–806.
30. Serruys PW, Silber S, Garg S et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136–46.
31. Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903–13.
32. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393–402.
33. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163–73.
34. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001; 59: 227–48.
35. Park KW, Kang SH, Velders MA et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J 2013; 165: 241–50 e244.
36. Greenhalgh J, Hockenhull J, Rao N et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 12: CD004587.
37. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P et al. Long-term benefit-risk balance of drug-eluting vs. Bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30: 16–24.
Авторы
А.И.Аналеев*1, С.П.Семитко1,2
1 ФГБУ ВПО Институт повышения квалификации ФМБА России. 125371, Россия, Москва, Волоколамское ш., д. 91;
2 ГБУЗ Городская клиническая больница им. В.В.Вересаева. 127644, Россия, Москва, ул. Лобненская, д. 10
*anton-analeev@yandex.ru
1 ФГБУ ВПО Институт повышения квалификации ФМБА России. 125371, Россия, Москва, Волоколамское ш., д. 91;
2 ГБУЗ Городская клиническая больница им. В.В.Вересаева. 127644, Россия, Москва, ул. Лобненская, д. 10
*anton-analeev@yandex.ru
________________________________________________
A.I.Analeev*1, S.P.Semitko1,2
1 Institute of Professional Development. 125371, Russian Federation, Moscow, Volokolamskoe sh., d. 91;
2 V.V.Veresaev Сity Clinical Hospital. 127644, Russian Federation, Moscow, ul. Lobnenskaia, d. 10
*anton-analeev@yandex.ru
1 Institute of Professional Development. 125371, Russian Federation, Moscow, Volokolamskoe sh., d. 91;
2 V.V.Veresaev Сity Clinical Hospital. 127644, Russian Federation, Moscow, ul. Lobnenskaia, d. 10
*anton-analeev@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.